<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027065</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-107-10</org_study_id>
    <secondary_id>2009-010709-35</secondary_id>
    <nct_id>NCT01027065</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients</brief_title>
  <acronym>CONVERT</acronym>
  <official_title>A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of &quot;CYT107&quot; (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytheris SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytheris SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety of biological active dose of a new experimental
      drug, IL-7, in combination with anti viral therapy and vaccine in patients with Hepatitis B
      chronic infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of
      Interleukin-7 (CYT107) in HBeAg-negative chronic hepatitis B infected adult patients. The
      dose escalation is aimed at establishing the safety of a biologically active doses of CYT107
      added to the current antiviral therapy with entecavir or tenofovir and vaccination or not. At
      each dose level, study patients will receive one subcutaneous administration of CYT107 per
      week for a total of 4.

      Groups of 8 patients will be entered at each dose level of CYT107. Three dose levels are
      planned.

      At each dose level, patients are randomized between 2 arms of treatment: tritherapy (CYT107,
      vaccine and antiviral treatment) or bitherapy (CYT107 and vaccine). Each treatment group is
      composed of 4 patients, 3 receiving experimental treatments, 1 just the current antiviral
      treatment (control patient).

      According to the treatment arm, eligible patients initially receive a vaccine if in treatment
      group of tritherapy, thereafter, CYT107 is added for a cycle of four weekly injections (if
      not a control patient) at a defined dose level. If in treatment group of tritherapy, patients
      will receive 2 additional doses of vaccine.

      The treatment phase for the tritherapy group is from first vaccine D0 to last vaccine W12 and
      includes CYT107 administration from W4 to W7.

      The treatment phase for the bitehrapy group is from W4 to W7 corresponding to CYT104
      injections.

      The patients are then followed on a regular basis until reaching 52 weeks after the D0.

      Participants will have 1 overnight hospitalization and 12 clinic visit on a period of 55
      weeks.

      During the visits the following may be done:

        -  medical history, physical examination, blood tests

        -  electrocardiograms (ECG)

        -  chest X-Ray

        -  liver/spleen imaging

        -  urine tests
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the short and long-term safety and biological activity of CYT107 in patients with a HBeAg-negative chronic hepatitis B who have, at screening a HBV DNA undetectable stable for at least 3 months with antiviral treatment.</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics and pharmacodynamics of CYT107 in humans chronically infected with HBV.</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the markers of the HBV infection (antiviral activity)at W16 weeks and W52</measure>
    <time_frame>Week 12 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To quantify the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the immune system at W16 weeks</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Tritherapy: CYT107+ vaccine+ antiviral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bitherapy: CYT107 + antiviral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT107+GenHevac+entecavir or tenofovir</intervention_name>
    <description>4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment</description>
    <arm_group_label>Tritherapy: CYT107+ vaccine+ antiviral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT107+ entecavir or tenofovir</intervention_name>
    <description>4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment</description>
    <arm_group_label>Bitherapy: CYT107 + antiviral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HBV-infected patients

          -  HBeAg-negative patients

          -  Age &gt; 18 years

          -  Patients with active chronic hepatitis at the start of the antiviral treatment

          -  Patient with a HBV DNA undetectable (&lt;70 copies/ml) stable for at least 3 months under
             entecavir or tenofovir treatment.

          -  Ongoing treatment by entecavir or tenofovir at screening Note: previous treatment with
             pegylated IFN monotherapy, before the start of entecavir or tenofovir, is acceptable

        Exclusion Criteria:

          -  Infection by HCV

          -  Infection by HIV-1 and /or HIV-2

          -  Apart from HBV infection, presence of active infection requiring a specific treatment
             or a hospitalization

          -  Previous treatment by lamivudine and/or nucleosides analogues

          -  Inactive carrier

          -  Cirrhosis

          -  Other liver disease (notably from alcoholic, metabolic or immunological origin)

          -  History of clinical autoimmune disease or active auto-immune disease

          -  Type I diabetes mellitus

          -  Severe asthma, presently on chronic medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Hezode</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Henri Mondor-Cr√©teil-France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pietro Andreone</last_name>
    <role>Principal Investigator</role>
    <affiliation>S. Orsola Malpighi- Bologna-Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Henri Mendor-Service d'HepatoGastroEnterologie</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Hotel Dieu</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria, Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interleukin-7</keyword>
  <keyword>immune-based therapies</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>HBe negative</keyword>
  <keyword>HBV vaccination</keyword>
  <keyword>entecavir</keyword>
  <keyword>tenofovir</keyword>
  <keyword>chronic hepatitis</keyword>
  <keyword>immune specific responses to HBV</keyword>
  <keyword>phase 1/2a</keyword>
  <keyword>viral disease</keyword>
  <keyword>liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

